喹硫平与利培酮治疗精神分裂症对照研究

A controlled study of quetiapine vs. risperidone in the treat- ment of schizophrenia

目的探讨喹硫平与利培酮治疗精神分裂症的临床疗效及安全性。方法将56例精神分裂症患者随机分为两组，每组28例，研究组口服喹硫平治疗，对照组口服利培酮治疗，观察8周。采用阳性与阴性症状量表及副反应量表评定临床疗效和不良反应，并于治疗前后测定血清催乳素水平。结果治疗8周末研究组显效率67．8％、有效率92．8％，对照组分别为64．2％、89．2％，两组比较差异无显著性（x2=0．08、0．22，P〉0．05）；研究组治疗前催乳素水平与对照组比较差异无显著性，治疗后显著低于对照组（P〈0．01）；两组不良反应均轻微，但研究组静坐不能、体质量增加及月经紊乱／泌乳发生率均显著低于对照组（P〈0．05）。结论喹硫平与利培酮治疗精神分裂症疗效均显著，但喹硫平治疗不引起体质量增加及催乳素水平升高，较少发生锥体外系反应，安全性更高，依从性更好。

To explore the efficacy and safety of quetiapine vs. risperidone in the treatment of schizophrema. Wletnoas r groups of 28 ones each, research group took orally cluetiapine and control group did risperidone for 8 weeks. Clinical efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） and ad- verse raections with the Treatment Emergent Symptom Scale （TESS）, serum proIactin levels detected be- fore after treatment. Results At the end of the 8＇h week obvious effective and effective rate were respec- tively 67.8~ and 92.8% in research and 64.2% and 89.2% in control group, which showed no significant differences （x2=0. 08, 0.22,P〈0.05） serum prolactin levels had no difference in research from control group before treatment, were significantly lower after treatment （P〈0.01） adverse reactions of both groups were mild, but the incidence of akathisia, weight gain, menstrual disorder/lactation were signifi- cantly lower in research than in control group （P〈0.05）. Conclusion Both quetiapine and risperidone are effective in schizophrenia, but cluetiapine doesn＇t cause weight gain and raise of prolactin levels, induces reactions of extrapyramidal system less, and has higher safety and better compliance.